| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 111.14M | 59.65M | 490.09M | 234.97M | 567.57M |
| Gross Profit | 68.24M | 34.65M | 465.09M | 209.97M | 542.26M |
| EBITDA | 568.73M | 26.21M | 451.90M | 195.97M | 533.53M |
| Net Income | 417.71M | -41.17M | 371.77M | 191.44M | 494.51M |
Balance Sheet | |||||
| Total Assets | 4.04B | 3.63B | 3.82B | 3.37B | 3.58B |
| Cash, Cash Equivalents and Short-Term Investments | 8.10M | 59.32M | 174.62M | 147.45M | 30.38M |
| Total Debt | 497.96M | 498.35M | 497.83M | 497.31M | 496.79M |
| Total Liabilities | 813.46M | 673.52M | 736.76M | 608.80M | 681.91M |
| Stockholders Equity | 3.07B | 2.83B | 2.96B | 2.64B | 2.77B |
Cash Flow | |||||
| Free Cash Flow | -31.66M | -103.44M | 66.61M | 152.34M | 61.09M |
| Operating Cash Flow | -31.66M | -103.44M | 66.61M | 152.34M | 61.09M |
| Investing Cash Flow | -9.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -10.62M | -8.42M | -37.25M | -35.58M | -51.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | C$355.06M | 1.90 | 19.86% | 1.47% | -73.34% | 40.59% | |
81 Outperform | C$355.06M | 1.90 | 19.86% | 1.43% | -73.34% | 40.59% | |
79 Outperform | C$1.21B | 7.10 | 9.85% | 3.01% | 11.23% | 30.44% | |
74 Outperform | C$817.83M | 1.28 | 9.23% | ― | 22.33% | -25.06% | |
71 Outperform | C$1.02B | 2.39 | 5.72% | 0.14% | -44.78% | -95.84% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
60 Neutral | ― | 4.06 | 1.97% | ― | -85.14% | -80.02% |
Fairfax India reported a sharp turnaround for 2025, posting net earnings of $410.5 million, or $3.05 per diluted share, versus a loss a year earlier, as book value per share rose 9.4% to $22.94 on strong gains from key Indian investments. Results were driven by sizable unrealized gains in holdings such as BIAL, IIFL Finance and CSB Bank, realized gains from the sale of its Saurashtra stake, and robust dividend and interest income, partially offset by foreign currency losses tied to the weaker Indian rupee.
The company increased its exposure to BIAL with an additional 10% stake funded under deferred terms supported by an expanded revolving credit facility, while continuing share buybacks that reduced its subordinate voting share count. With $50.7 million in cash and marketable securities and $168.5 million of undrawn credit at year-end, Fairfax India underscored its strong liquidity, giving it flexibility to pursue further investments in India and maintain capital allocation initiatives that may benefit shareholders over time.